November 17, 2009 (Orlando, Florida) — Advanced heart-failure transplant-ineligible patients with Thoratec's HeartMate II continuous-flow left-ventricular assist device (LVAD) have better-than-even ...

Washington, DC - Data from 64 HeartMate II (Thoratec) left ventricular assist device (LVAD) patients treated at the Henry Ford Hospital in Detroit suggest that many of the patients implanted with the ...

Thoratec Corp. THOR recently presented positive data for its HeartMate II heart pump device from the ENDURANCE destination therapy trial at the 35th Annual Meeting and Scientific Sessions of the ...

The FDA has granted approval of Thoratec’s HeartMate II left ventricular assist device, allowing the use of the device for destination therapy. The approval allows the HeartMate II to be used in ...

ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate® II LVAS (Left ...

Thoratec's HeartMate II left ventricular assist device--Courtesy of Thoratec Thoratec ($THOR) said that two patients died and one suffered a serious injury after they ...

Shares of St. Jude Medical Inc.STJ rose nearly 2.2% yesterday, following the CE Mark approval for HeartMate 3 Left Ventricular Assist System (LVAS) in Europe. The company will start to commercialize ...